focus -WSS

focus

author：entertainment 2025-08-20 09:41:38 - browse：331

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Elisabeth Bik tackles the widespread issue of research misconduct

WSS

Childhood vaccination ad campaign launches in the U.K.

Medical devices makers are asking for forgiveness, not permission

Study fuels hope CAR

Testing GLP

Medicare Advantage insurers pressure Biden for bigger payments

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

entertainment

focus

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast, live from the STAT Breakthrough Summit East

In Memoriam: Notable people who died in 2023

With Wegovy coverage, Medicare patients may face high costs

Walensky prepares to leave CDC — and Congress — behind

Pfizer, Moderna say biotech, pharma drug development is a sprint

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Doctor of U.S. President Joe Biden says he is fit for duty

hotspot

Children’s Hospital revives plan for pedestrian bridge

Medical devices makers are asking for forgiveness, not permission

CDC advisory group OKs chikungunya vaccine

Neuroscience renaissance leads to new crop of psychiatric drugs

STAT Madness 2024: Meet the contenders

Ohio train derailment: Experts on toxic chemical risks

entertainment

focus

entertainment

Wikipedia